Biomimetic Innovations Ltd

Biomimetic Innovations Ltd focuses on creating innovative biomaterials for medical applications. The company was founded in 2023 and is located in Shannon, Ireland. Following its establishment, it has successfully completed 1 deal. The latest funding round took place on January 24, 2025, raising EUR 8 million from investor Sanara MedTech Inc.

The total amount raised by the company amounts to EUR 8 million. The founder's background is currently not available. Biomimetic Innovations Ltd specializes in the development and commercialization of OsStic®, a synthetic biomaterial technology designed for skeletal and soft tissue repair. This innovative product enhances structural stability in bone, thereby assisting in the healing process through its biomimetic mechanism of action.

OsStic® functions as a synthetic injectable bone void filler, providing mechanical support and bioadhesive properties that promote faster remodeling and stabilization of implants, particularly in patients with poor bone quality. The technology has applications in trauma, spinal, and dental surgery, serving a diverse client base that includes clinicians and medical institutions in both veterinary and human healthcare. Biomimetic Innovations markets its products primarily in the United States and Europe, with operational facilities in France and Tennessee, ensuring a robust presence in these key geographical markets. Biomimetic Innovations generates revenue through the direct sale of its flagship product, OsStic®, to healthcare providers and institutions engaged in surgical procedures.

Transactions typically occur on a B2B basis, where hospitals and surgical centers purchase OsStic® for use in various medical applications. The pricing structure for these products is established through agreements with healthcare providers, ensuring that the products meet the specific needs of clinicians and their patients. Biomimetic Innovations is focused on expanding its market reach and enhancing partnerships with medical entities to drive further adoption of its innovative technologies. The company's revenue model is supported by its ISO 13485 accredited facility, which underlines its commitment to quality and regulatory compliance in the medical device industry.

In January 2025, Biomimetic Innovations Ltd raised EUR 8 million in venture funding from Sanara MedTech Inc. The company plans to utilize this funding to enhance its medical equipment manufacturing and processes. Biomimetic Innovations is also focused on designing and launching new products aimed at improving patient outcomes, with specific timelines for release yet to be announced. Additionally, the company has plans to expand into new markets in Europe and North America by the end of 2025.